Led by $600m venture financing of CMR Surgical, total medical devices industry cross border venture financing deals worth $1.4bn were announced in Europe in Q2 2021, according to GlobalData’s deals database.
Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 856.8% over the previous quarter and a rise of 574.8% when compared with the last four-quarter average of $210.43m.
Europe held a 30.21% share of the global medical devices industry cross border venture financing deal value that totalled $4.7bn in Q2 2021. With a 22.98% share and deals worth $1.08bn, the UK was the top country in Europe’s cross border venture financing deal value across medical devices industry.
In terms of deal activity, Europe recorded 30 cross border deals during Q2 2021, marking an increase of 87.50% over the previous quarter and a rise of 66.67% over the last four-quarter average. The UK recorded 11 deals during the month.
Europe medical devices industry cross border venture financing deals in Q2 2021: Top deals
The top five cross border venture financing deals accounted for 82.9% of the overall value during Q2 2021.
The combined value of the top five medical devices cross border venture financing deals stood at $1.18bn, against the overall value of $1.4bn recorded for the quarter.
The top five medical devices cross border deals of Q2 2021 tracked by GlobalData were:
1) Ally Bridge Group, Cambridge Innovation Capital, Chimera Partners, GE Healthcare, LGT Impact Ventures, Lightrock, PFM Health Sciences, RPMI Railpen, SoftBank Vision Fund II, Tencent Holdings and Watrium’s $600m venture financing of CMR Surgical
2) The $245m venture financing of Quanta Dialysis Technologies by BlackRock, btov Partners, Eldridge Industries, Glenview Capital Management, Millennium Management, Monashee Investment Management, Novo Holdings, Orlando Health, Puhua Capital, Sands Capital Management, Segulah, Seroba Life Sciences Management and Wellington Partners
3) HAT SGR, Hitachi Ventures, Leaps by Bayer, Samsung NEXT Fund, Sony Innovation Fund and Unilever Ventures’ $130m venture financing of Huma Therapeutics
4) The $115m venture financing of CeQur by Credit Suisse Entrepreneur Capital, Endeavour Vision, Federated Hermes Kaufmann Fund, GMS Capital, Kingdon Capital Management, SchroderBank AG, Tandem Diabetes Care, VI Partners and Ypsomed
5) F4 Investments, Inteligo Bank, Leaps by Bayer, Mutschler Ventures, Samsung Catalyst Fund and Vitruvian Partners’ venture financing of Ada Health for $90m.